Category: by country

Analysis of pilots with prostate cancer retracted for “inappropriate data”

Aerospace Medicine and Human PerformanceIn case any pilots out there are worrying about their risk of prostate cancer based on a recent meta-analysis that found they are at least twice as likely to develop the disease, they should relax — the paper has been retracted.

The reason: “including inappropriate data from two studies that should be ineligible.”

“The risk of prostate cancer in pilots: a meta-analysis” reviewed eight studies to determine whether airline pilots, who are regularly exposed to radiation and other occupational hazards, have a higher incidence of prostate cancer. However, it also included studies that reported on prostate cancer among all U.S. Armed Forces servicemen, not pilots.

The retraction notice was posted in May — only months after it was published in Aerospace Medicine and Human Performance in February. The notice included a letter to the editor outlining flaws in the meta-analysis and an apologetic response from first author, David Raslau at the Mayo Clinic.

Here’s the notice (appearing at the bottom of page 2):

Continue reading Analysis of pilots with prostate cancer retracted for “inappropriate data”

“Exactly the same clinical study” published six times

4A group of researchers conducted a clinical trial on hundreds of hypertensive patients. Then, they published the results…six times.

The “nearly identical” papers came to our attention via a retraction in Inflammation. Editor in chief Bruce Cronstein explained how he learned of the mass duplication:

The editors were contacted en masse by somebody doing a Cochrane Review on hypertension and who noticed that the content of the 6 papers was nearly identical.  Frankly, not one of us would have noticed otherwise.

Another of those papers, in the European Journal of Pharmaceutical Sciences, has also been retracted. That note is similar to the retraction notice for the Inflammation paper, both of which have been cited twice:

Continue reading “Exactly the same clinical study” published six times

Running shoe paper pulled for failing to disclose author’s industry ties

87507315-105.4.coverNot so fast — a paper that showed wearing Vibram FiveFingers (resembling foot gloves) “may help reduce running-related injuries” has been removed after the editors realized the first author is on Vibram’s advisory board.

Managing editor Noelle A. Boughanmi told us there’s no retraction here — the journal is just fixing the paper to address the relationship of podiatrist Nick Campitelli with the company featured in the article.

There is still a copy of the paper on PubMed, which suggests these “minimalist shoes” strengthen key muscles.

The paper was published online by the Journal of the American Podiatric Medical Association. It was removed after editors realized that “the author did not fully disclose some involvement with the company,” Boughanmi said:

Continue reading Running shoe paper pulled for failing to disclose author’s industry ties

Trouble with data proves toxic for a pair of toxicology papers

logoA pair of papers about the risks of titanium dioxide nanoparticles that share many of the same authors has been retracted from a toxicology journal following an investigation at Soochow University in China.

Particle and Fibre Toxicology is retracting the papers for problems with the statistical methods and missing data, as well as for sharing figures.

Here’s the note for “Intragastric exposure to titanium dioxide nanoparticles induced nephrotoxicity in mice, assessed by physiological and gene expression modifications:”

Continue reading Trouble with data proves toxic for a pair of toxicology papers

“Disagreement about the relative contributions” of authors burns capacitor paper

S02663538A 2014 paper on a component for thin electric circuits has been retracted from Composites Science and Technology due to a “disagreement” over author contributions, according to the retraction note.

The retraction note for “Preparation and dielectric properties of BaTiO3:epoxy nanocomposites for embedded capacitor application” is short and sweet. Here it is, in full:

Continue reading “Disagreement about the relative contributions” of authors burns capacitor paper

Gold nanoparticle paper crushed by “deliberate and fraudulent use of data”

8

Biotechnology Letters has retracted a paper on a new gene delivery technique due to “the deliberate and fraudulent use of data in the paper that had previously appeared in other papers of these two authors.”

The journal’s Editor in Chief Colin Ratledge told us that someone tipped him off that one of the authors, University of Kalyani microbiologist Keka Sarkar, had been self-plagiarizing:

I can say that a person who was familiar with the work of Dr Sarkar got in touch with about their concerns about her publications and, in particular, her paper published in Biotechnology Letters.  They supplied a dossier of her publications showing the obvious duplications of figures and that she had been using the same figures in different papers to illustrate the results from supposedly different experiments.

He found that, indeed, multiple figures in the Biotechnology Letters had appeared in other publications of Sarkar’s, some prior to the paper’s October 2013 publication, and one after. The details are in the whole retraction note:
Continue reading Gold nanoparticle paper crushed by “deliberate and fraudulent use of data”

Three more retractions for former record-holder Boldt, maybe more to come

m_cover

Justus Liebig University in Germany has been investigating concerns that Joachim Boldt, number two on the Retraction Watch Leaderboard and now up to 92 retractions, may have “manipulated” more data than previously believed.

Until now, the vast majority of Boldt’s retractions were thought to have involved inadequate ethics approval. However, new retraction notices for Boldt’s research suggest that there’s evidence the researcher also engaged in significant data manipulation.

The first retraction from the university investigation emerged last year. Two of three new notices cite the investigation specifically, and an informant at the university told us that there are more retractions to come.

Here are the retracted papers that are freshly on the record, starting with an August retraction for a 1991 Anesthesiology paper (cited 37 times, according to Thomson Scientific’s Web of Knowledge):

Continue reading Three more retractions for former record-holder Boldt, maybe more to come

BMC editors update retraction after investigation clears authors of faking peer reviews

bmc-logo

Editors at BioMed Central have taken the unusual step of updating a retraction notice after an investigation found the authors were not responsible for a peer review process gone awry. The paper is one of  dozens of other papers retracted in March for fake peer reviews.

That month, the paper “Clinical application of contrast enhanced ultrasound to diagnose benign prostatic hyperplasia” in Diagnostic Pathology was among the 43 papers retracted due to fake peer reviews. (Retractions for the phenomenon — more about it in our Nature feature here — are up to about 170.)

According to the update posted in July, an investigation into the paper by the Jiading Central Hospital in Shanghai, where the authors work, found that they “did not participate in influencing the peer review process.”

Here’s more from the update to the notice:

Continue reading BMC editors update retraction after investigation clears authors of faking peer reviews

Drugmaker accused of omitting side effect data from 2003 Risperdal paper

cover7607A 2003 paper may have left out potentially “significant” data on the long-term side-effects of an antipsychotic drug used in children, according to a former head of the U.S. Food and Drug Administration.

As reported by the Toronto Star, David Kessler is alleging that Janssen, the maker of Risperdal (and owned by Johnson & Johnson), omitted data about the risks of the drug: In particular, that boys who use it over a long period may be at risk of growing breasts.

There’s anecdotal evidence of the side effect. One family claimed the drug had caused their son to grow a pair of 46 DD-sized breasts in a lawsuit against Johnson & Johnson, reported the Wall Street Journal in February. They won, to the tune of $2.5 million. The suit is apparently just one of 1,200 like it.

The abstract of the paper, “Prolactin levels during long-term risperidone treatment in children and adolescents,” published in The Journal of Clinical Psychiatry, suggests that levels of a key hormone aren’t a problem in the long term:

Continue reading Drugmaker accused of omitting side effect data from 2003 Risperdal paper

Eighth retraction published for former physiology researcher

International Journal of CancerA lung cancer paper in the International Journal of Cancer has been retracted because of “serious errors related to image duplication.” This marks the eighth retraction for first author, ShouWei Han.

The decision was made by the journal’s editor-in-chief, the publisher Wiley and co-author Jesse Roman (a co-author on Han’s other retracted papers). According to the notice, Han didn’t respond “to requests by the journal or the co-author.”

In 2011, Han was the target of an investigation by his former employer, the University of Louisville in Kentucky. Papers in the Journal of Biological Chemistry, the American Journal of Respiratory Cell and Molecular Biology and American Journal of Physiology: Lung Cellular and Molecular Physiology have been retracted.

Here’s the full retraction notice for the latest retraction:

Continue reading Eighth retraction published for former physiology researcher